Gastric Cancer

, Volume 12, Issue 2, pp 69–78

Paclitaxel chemotherapy for the treatment of gastric cancer

  • Junichi Sakamoto
  • Takanori Matsui
  • Yasuhiro Kodera
Review Article

DOI: 10.1007/s10120-009-0505-z

Cite this article as:
Sakamoto, J., Matsui, T. & Kodera, Y. Gastric Cancer (2009) 12: 69. doi:10.1007/s10120-009-0505-z

Abstract

A comprehensive review of phase I and phase II clinical trials of paclitaxel and paclitaxel-containing chemotherapy regimens for advanced gastric cancer was performed. Response rates, median progression-free survivals, and median overall survivals were examined, together with the treatment regimens and the numbers of patients registered in each trial. Although paclitaxel monotherapy produced considerable improvement in tumor response and prognosis, combination doublet or triplet chemotherapy with fluoropyrimidines and/or platinum compounds showed better results than the paclitaxel monotherapy. With regard to the schedule of paclitaxel administration, weekly injection seemed to show less toxicity and better results than administration every 3 weeks. Adjuvant therapies, chemoradiation therapies, and paclitaxel treatment for gastric ascites were also investigated and are discussed.

Key words

Paclitaxel Gastric cancer Chemotherapy 
Download to read the full article text

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2009

Authors and Affiliations

  • Junichi Sakamoto
    • 1
  • Takanori Matsui
    • 2
  • Yasuhiro Kodera
    • 3
  1. 1.Department of Young Leaders’ Program in Medical AdministrationNagoya University Graduate School of MedicineAichiJapan
  2. 2.Department of SurgeryAichi Cancer Center, Aichi HospitalOkazakiJapan
  3. 3.Department of Digestive SurgeryNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations